Roche & BSBE Signed a Cooperation Agreement on Clinical Biochemistry Reagents
On March 4th, 2016, Roche Diagnostics <Shanghai> (hereinafter referred to as Roche) and Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) hold a signing ceremony of cooperation agreement on clinical biochemistry reagents in Shanghai, which officially opens a new chapter to forge ahead and creates success together in China market.
Under the terms of the agreement, BSBE should supply clinical biochemistry reagents which are compatible with Roche Cobas c701/702, Cobas c501/502, Cobas c311, Modular P and other series of clinical biochemistry analyzers to Roche for promoting its sales in China. And the first cooperation project should include 21 analytes.
Mr. Boxing Huang, General Manager of Roche China
“Over the years, Roche Diagnostics is committed itself to provide a total solution for the Chinese customers in laboratories, including high throughput testing platform, comprehensive reagent analysis menu, accurate and reliable results, professional and 360 degree technical support service. Meanwhile, Roche Diagnostics is actively seeking reliable partners to continuously improve our analysis system, in order to provide better service to our customers.”
Mr. Zuojun Zou, President of BSBE
“Roche Diagnostics, as one of the world's leading enterprises, which BSBE has been committed to looking for the cooperation opportunity for a partnership. Through the cooperation, the two parties can further expand their market share in the field of clinical biochemistry diagnosis, which has positive significance for the development of both enterprises. This cooperation also indicates that the recognition from Roche Diagnostics in R&D, production and QC of BSBE. BSBE will also cherish this rare chance, with mutual communication and studying, constantly improve itself to provide better services to the customers.”
Mr. Jintian Chen, BU Director of Roche China
The signing of the agreement embodies BSBE’s development strategy of “Running with the Giants” and also shows itself has reached to international level in R&D, quality control and etc. Through this cooperation, Roche Diagnostics will integrate new analytes into this existing menu of clinical biochemistry analysis and provide customers with more comprehensive clinical biochemistry products. By promoting the application of new analytes in the China domestic market to assist customers to continuously improve the level of diagnosis. Meanwhile, BSBE shows its interest in cooperating with Roche’s clinical biochemistry analyzers, which will expand the high-level customers, which positively impact its future sales performance. And this will continuously consolidate its leading position in the field of biochemical reagents in China.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
Founded in 1896, Roche has been making important contributions to global healthcare for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2015, the Roche Group employed 91,700 people worldwide, invested 9.3 billion Swiss francs in R&D and posted sales of 48.1 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. (For more information, please visit www.roche.com).
Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) is a high growth company and the main businesses are R&D, manufacturing and sales in clinical biochemistry diagnosis system. BSBE develops series of products with the international development synchronously. BSBE always focuses on the R&D of new products and has very strong research and innovation ability in the field of clinical biochemistry reagents. As the China domestic leader in IVD filed, BSBE owns a full range of diagnostic reagents, and some of the new products have been awarded the innovation award in China. BSBE now has a number of patents. In recent years, BSBE has always achieved rapid development and the sales and profitability come out in the front among the domestic IVD competitors. BSBE has been on the list of "Forbes China's most potential small and medium-sized enterprises" for nine years continuously. On October 30th, 2014, BSBE was successfully listed on GEM in Shenzhen, with the stock code 300406.